Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2012-06-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model
NCT06161870
Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation
NCT01925066
Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients
NCT01157533
Vancomycin in the Target Site Treatment of Intracranial Infection
NCT03585426
Vancomycin Dosage Adjustment for MRSA Infections
NCT03412500
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Vancomycin : a glycopeptide antibiotic, is the first line agent in the treatment of methicillin resistant staphylococcus aureus
Study design : Randomized controlled trials
Study Drug Administration
* If your doctor believes you are eligible, and you agree to take part in this study, you will be randomized to two treatment groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vancomcyin, maintain dose
This arm is received only maintain dose of vancomycin (15mg/kg twice a day or 1g twice a day).
No interventions assigned to this group
Vancomycin loading
This group is received loading dose 30mg/kg. Subsequent doses of vancomycin are considered standard of care.
Vancomycin HCL
Loading dose of 30mg/kg via central or peripheral intravenous infusion during 2 or 3 hours.
Maintenance dose of vancomycin is 15mg/kg twice a day or 1g twice a day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vancomycin HCL
Loading dose of 30mg/kg via central or peripheral intravenous infusion during 2 or 3 hours.
Maintenance dose of vancomycin is 15mg/kg twice a day or 1g twice a day.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with SIRS (systemic inflammatory response syndrome)
* Intravenous vancomycin therapy deemed necessary
Exclusion Criteria
* Age more than 75 years
* Current renal insufficiency defined as estimated Glomerular filtration rate \< 50mg/min/1.73 m2 by MDRD equation
* History of adverse events to vancomycin 5. Pregnant woman
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyong Ran Peck, MD
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-09-067
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.